International Journal of Cancer Management

Published by: Kowsar

Immunohistochemical Expression of Ki67 and HER2 in Colorectal Cancer Compared to Adenomatous and Normal Samples

Zahra Heidari 1 , 2 , Hamidreza Mahmoudzadeh-Sagheb 1 , 2 , Mehdi Jahantigh 3 and Enam Alhagh Charkhat Gorgich 2 , *
Authors Information
1 Infectious Diseases and Tropical Medicine Research Center, Zahedan University of Medical Sciences, Zahedan, Iran
2 Department of Histology, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran
3 Department of Pathology, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran
Article information
  • International Journal of Cancer Management: November 2017, 10 (11); e12252
  • Published Online: November 30, 2017
  • Article Type: Research Article
  • Received: April 29, 2017
  • Revised: July 4, 2017
  • Accepted: November 18, 2017
  • DOI: 10.5812/ijcm.12252

To Cite: Heidari Z, Mahmoudzadeh-Sagheb H, Jahantigh M, Charkhat Gorgich E A. Immunohistochemical Expression of Ki67 and HER2 in Colorectal Cancer Compared to Adenomatous and Normal Samples, Int J Cancer Manag. 2017 ; 10(11):e12252. doi: 10.5812/ijcm.12252.

Abstract
Copyright © 2017, Cancer Research Center (CRC), Shahid Beheshti University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Methods
3. Results
4. Discussion
Acknowledgements
Footnotes
References
  • 1. Stewart B, Wild CP. World Cancer Report 2014. World; 2016.
  • 2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90. doi: 10.3322/caac.20107. [PubMed: 21296855].
  • 3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74-108. doi: 10.3322/canjclin.55.2.74. [PubMed: 15761078].
  • 4. Khuhaprema T, Srivatanakul P. Colon and rectum cancer in Thailand: an overview. Jpn J Clin Oncol. 2008;38(4):237-43. doi: 10.1093/jjco/hyn020. [PubMed: 18356191].
  • 5. Malekzadeh R, Bishehsari F, Mahdavinia M, Ansari R. Epidemiology and molecular genetics of colorectal cancer in iran: a review. Arch Iran Med. 2009;12(2):161-9. [PubMed: 19249887].
  • 6. Sameer AS, Abdullah S, Syeed N, Siddiqi MA. Colorectal cancer, TGF-signaling and SMADs. Int J Genet Mol Biol. 2010;2(6):101-11.
  • 7. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61(5):759-67. doi: 10.1016/0092-8674(90)90186-I. [PubMed: 2188735].
  • 8. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature. 1998;396(6712):643-9. doi: 10.1038/25292. [PubMed: 9872311].
  • 9. Gonzalez CA. Nutrition and cancer: the current epidemiological evidence. Br J Nutr. 2006;96 Suppl 1:S42-5. doi: 10.1079/BJN20061699. [PubMed: 16923250].
  • 10. Manju V, Nalini N. Chemopreventive efficacy of ginger, a naturally occurring anticarcinogen during the initiation, post-initiation stages of 1,2 dimethylhydrazine-induced colon cancer. Clin Chim Acta. 2005;358(1-2):60-7. doi: 10.1016/j.cccn.2005.02.018. [PubMed: 16018877].
  • 11. Klurfeld DM. Dietary fiber-mediated mechanisms in carcinogenesis. Cancer Res. 1992;52(7 Suppl):2055s-9s. [PubMed: 1311988].
  • 12. Fuchs CS, Giovannucci EL, Colditz GA, Hunter DJ, Stampfer MJ, Rosner B, et al. Dietary fiber and the risk of colorectal cancer and adenoma in women. N Engl J Med. 1999;340(3):169-76. doi: 10.1056/NEJM199901213400301. [PubMed: 9895396].
  • 13. Ensani F, Hajsadeghi N. Iran J Surg. Evaluation of predictive and prognostic factors and their effects on survival rate in a group of patients with breast carcinoma and long term follow up in cancer institute. 2005;13(2):69-76.
  • 14. Lindboe CF, Torp SH. Comparison of Ki-67 equivalent antibodies. J Clin Pathol. 2002;55(6):467-71. doi: 10.1136/jcp.55.6.467. [PubMed: 12037032].
  • 15. Melling N, Kowitz CM, Simon R, Bokemeyer C, Terracciano L, Sauter G, et al. High Ki67 expression is an independent good prognostic marker in colorectal cancer. J Clin Pathol. 2016;69(3):209-14. doi: 10.1136/jclinpath-2015-202985. [PubMed: 26281861].
  • 16. Leek RD. The prognostic role of angiogenesis in breast cancer. Anticancer Res. 2001;21(6B):4325-31. [PubMed: 11908687].
  • 17. de Azambuja E, Cardoso F, de Castro GJ, Colozza M, Mano MS, Durbecq V, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer. 2007;96(10):1504-13. doi: 10.1038/sj.bjc.6603756. [PubMed: 17453008].
  • 18. Zhao WY, Xu J, Wang M, Zhang ZZ, Tu L, Wang CJ, et al. Prognostic value of Ki67 index in gastrointestinal stromal tumors. Int J Clin Exp Pathol. 2014;7(5):2298-304. [PubMed: 24966939].
  • 19. Yamaguchi T, Fujimori T, Tomita S, Ichikawa K, Mitomi H, Ohno K, et al. Clinical validation of the gastrointestinal NET grading system: Ki67 index criteria of the WHO 2010 classification is appropriate to predict metastasis or recurrence. Diagn Pathol. 2013;8:65. doi: 10.1186/1746-1596-8-65. [PubMed: 23607525].
  • 20. Mahmoudzadeh Sagheb H, Heidari Z, Jahantigh M, Narouei M. Immunohistochemical Expression of p53 and Ki-67 Genes in Gastric Cancer and Precancerous Lesions in the Patients with Helicobacter pylori Infection. Gene Cell Tissue. 2016;3(4). doi: 10.17795/gct-41341.
  • 21. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19(9):1523-9. doi: 10.1093/annonc/mdn169. [PubMed: 18441328].
  • 22. Olayioye MA. Intracellular signaling pathways of ErbB2/HER-2 and family members. Breast Cancer Res. 2001;3(6). doi: 10.1186/bcr327.
  • 23. Lee HE, Park KU, Yoo SB, Nam SK, Park DJ, Kim HH, et al. Clinical significance of intratumoral HER2 heterogeneity in gastric cancer. Eur J Cancer. 2013;49(6):1448-57. doi: 10.1016/j.ejca.2012.10.018. [PubMed: 23146959].
  • 24. Wagner AD, Wedding U. Advances in the pharmacological treatment of gastro-oesophageal cancer. Drugs Aging. 2009;26(8):627-46. doi: 10.2165/11315740-000000000-00000. [PubMed: 19685930].
  • 25. Heidari Z, Mahmoudzadeh Sagheb H, Charkhat Gorgich EAC. Immunohistochemical expression of P16ink4a in colorectal adenocarcinoma compared to adenomatous and normal tissue samples: A study on Southeast Iranian samples. Iran Red Crescent Med. 2017;19(6). doi: 10.5812/ircmj.15174.
  • 26. Kreisberg JI, Malik SN, Prihoda TJ, Bedolla RG, Troyer DA, Kreisberg S, et al. Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res. 2004;64(15):5232-6. doi: 10.1158/0008-5472.CAN-04-0272. [PubMed: 15289328].
  • 27. Feng YZ, Shiozawa T, Miyamoto T, Kashima H, Kurai M, Suzuki A, et al. Overexpression of hedgehog signaling molecules and its involvement in the proliferation of endometrial carcinoma cells. Clin Cancer Res. 2007;13(5):1389-98. doi: 10.1158/1078-0432.CCR-06-1407. [PubMed: 17332280].
  • 28. Ma YL, Peng JY, Zhang P, Liu WJ, Huang L, Qin HL. Immunohistochemical analysis revealed CD34 and Ki67 protein expression as significant prognostic factors in colorectal cancer. Med Oncol. 2010;27(2):304-9. doi: 10.1007/s12032-009-9210-3. [PubMed: 19340613].
  • 29. Zong L, Chen P, Wang DX. Death decoy receptor overexpression and increased malignancy risk in colorectal cancer. World J Gastroenterol. 2014;20(15):4440-5. doi: 10.3748/wjg.v20.i15.4440. [PubMed: 24764685].
  • 30. Hofmann M, Stoss O, Shi D, Buttner R, van de Vijver M, Kim W, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52(7):797-805. doi: 10.1111/j.1365-2559.2008.03028.x. [PubMed: 18422971].
  • 31. Lin MX, Wen ZF, Feng ZY, He D. [Expression and significance of Bmi-1 and Ki67 in colorectal carcinoma tissues]. Ai Zheng. 2008;27(12):1321-6. [PubMed: 19080002].
  • 32. Folkman J. Angiogenesis and breast cancer. J Clin Oncol. 1994;12(3):441-3. doi: 10.1200/JCO.1994.12.3.441. [PubMed: 7509850].
  • 33. Menezes HL, Juca MJ, Gomes EG, Nunes BL, Costa HO, Matos D. Analysis of the immunohistochemical expressions of p53, bcl-2 and Ki-67 in colorectal adenocarcinoma and their correlations with the prognostic factors. Arq Gastroenterol. 2010;47(2):141-7. doi: 10.1590/S0004-28032010000200005. [PubMed: 20721457].
  • 34. Lumachi F, Orlando R, Marino F, Chiara GB, Basso SM. Expression of p53 and Ki-67 as prognostic factors for survival of men with colorectal cancer. Anticancer Res. 2012;32(9):3965-7. [PubMed: 22993345].
  • 35. Salminen E, Palmu S, Vahlberg T, Roberts PJ, Soderstrom KO. Increased proliferation activity measured by immunoreactive Ki67 is associated with survival improvement in rectal/recto sigmoid cancer. World J Gastroenterol. 2005;11(21):3245-9. doi: 10.3748/wjg.v11.i21.3245. [PubMed: 15929175].
  • 36. Palmqvist R, Sellberg P, Oberg A, Tavelin B, Rutegard JN, Stenling R. Low tumour cell proliferation at the invasive margin is associated with a poor prognosis in Dukes' stage B colorectal cancers. Br J Cancer. 1999;79(3-4):577-81. doi: 10.1038/sj.bjc.6690091. [PubMed: 10027333].
  • 37. Pollack A, DeSilvio M, Khor LY, Li R, Al-Saleem TI, Hammond ME, et al. Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02. J Clin Oncol. 2004;22(11):2133-40. doi: 10.1200/JCO.2004.09.150. [PubMed: 15169799].
  • 38. Gorgich EAC, Heidari Z, Mahmoudzadeh-Sagheb H. P16ink4a Subcellular Expression Patterns in Colorectal Adenocarcinoma, Adenoma and Non-Neoplastic Tissue Samples. Asian Pac J Cancer Prev. 2017;18(11):3049-54. doi: 10.22034/APJCP.2017.18.11.3049. [PubMed: 29172278].
  • 39. Hashimoto Y, Skacel M, Lavery IC, Mukherjee AL, Casey G, Adams JC. Prognostic significance of fascin expression in advanced colorectal cancer: an immunohistochemical study of colorectal adenomas and adenocarcinomas. BMC Cancer. 2006;6:241. doi: 10.1186/1471-2407-6-241. [PubMed: 17029629].
  • 40. Han JS, Cao D, Molberg KH, Sarode VR, Rao R, Sutton LM, et al. Hormone receptor status rather than HER2 status is significantly associated with increased Ki-67 and p53 expression in triple-negative breast carcinomas, and high expression of Ki-67 but not p53 is significantly associated with axillary nodal metastasis in triple-negative and high-grade non-triple-negative breast carcinomas. Am J Clin Pathol. 2011;135(2):230-7. doi: 10.1309/AJCP9DV3EVZUATFV. [PubMed: 21228363].
  • 41. Nicolini A, Carpi A, Tarro G. Biomolecular markers of breast cancer. Front Biosci. 2006;11:1818-43. doi: 10.2741/1926. [PubMed: 16368559].
  • 42. Toiyama Y, Yasuda H, Saigusa S, Tanaka K, Inoue Y, Goel A, et al. Increased expression of Slug and Vimentin as novel predictive biomarkers for lymph node metastasis and poor prognosis in colorectal cancer. Carcinogenesis. 2013;34(11):2548-57. doi: 10.1093/carcin/bgt282. [PubMed: 24001454].
  • 43. Blok EJ, Kuppen PJ, van Leeuwen JE, Sier CF. Cytoplasmic Overexpression of HER2: a Key Factor in Colorectal Cancer. Clin Med Insights Oncol. 2013;7:41-51. doi: 10.4137/CMO.S10811. [PubMed: 23471238].
  • 44. Kruszewski WJ, Rzepko R, Ciesielski M, Szefel J, Zielinski J, Szajewski M, et al. Expression of HER2 in colorectal cancer does not correlate with prognosis. Dis Markers. 2010;29(5):207-12. doi: 10.3233/DMA-2010-0742. [PubMed: 21206005].
  • 45. Essapen S, Thomas H, Green M, De Vries C, Cook MG, Marks C, et al. The expression and prognostic significance of HER-2 in colorectal cancer and its relationship with clinicopathological parameters. Int J Oncol. 2004;24(2):241-8. [PubMed: 14719098].
  • 46. Seo AN, Kwak Y, Kim DW, Kang SB, Choe G, Kim WH, et al. HER2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expression. PLoS One. 2014;9(5). e98528. doi: 10.1371/journal.pone.0098528. [PubMed: 24879338].
  • 47. Ingold Heppner B, Behrens HM, Balschun K, Haag J, Kruger S, Becker T, et al. HER2/neu testing in primary colorectal carcinoma. Br J Cancer. 2014;111(10):1977-84. doi: 10.1038/bjc.2014.483. [PubMed: 25211663].
  • 48. Lim SD, Cho YM, Choi GS, Park HK, Paick SH, Kim WY, et al. Clinical Significance of Substaging and HER2 Expression in Papillary Nonmuscle Invasive Urothelial Cancers of the Urinary Bladder. J Korean Med Sci. 2015;30(8):1068-77. doi: 10.3346/jkms.2015.30.8.1068. [PubMed: 26240484].
  • 49. Kafi SG, Lari S, Nassiri G. HER2/neu expression in colon adenocarcinoma and its correlation with clinicopathologic variables. Iran J Basic Med Sci. 2006;9(1):64-9.
  • 50. Park DI, Oh SJ, Park SH, Yun JW, Kim HJ, Cho YK, et al. [Clinical significance of HER-2/neu expression in colon cancer]. Korean J Gastroenterol. 2004;44(3):147-52. [PubMed: 15385723].
  • 51. Bellmunt J, Werner L, Bamias A, Fay AP, Park RS, Riester M, et al. HER2 as a target in invasive urothelial carcinoma. Cancer Med. 2015;4(6):844-52. doi: 10.1002/cam4.432. [PubMed: 25720673].
  • 52. Kunz PL, Mojtahed A, Fisher GA, Ford JM, Chang DT, Balise RR, et al. HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. Appl Immunohistochem Mol Morphol. 2012;20(1):13-24. doi: 10.1097/PAI.0b013e31821c821c. [PubMed: 21617522].
  • 53. Delektorskaia VV, Perevoshchikov AG, Kushlinskii NE. [Expression of nm23 and c-erbB-2 proteins in cells of primary colorectal cancer and its metastases]. Arkh Patol. 2003;65(5):11-5. [PubMed: 14664140].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments